Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Personalized blood-thinner plan for leg artery disease after repair

Official title: Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease

Run by Massachusetts General Hospital · NCT07613840 · Data updated 2026-11-12

A personalized plan using a blood test to tailor antiplatelet therapy is being tested against standard treatment in adults with PAD after a procedure to restore blood flow.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment484 (estimated)
SponsorMassachusetts General Hospital
Academic / other
Locations2 sites (Boston, Massachusetts and 1 other locations)
StatusRecruiting
StartedApril 29, 2025
Main results expectedApril 29, 2027
Study endsJune 30, 2027
Registry record updatedSeptember 11, 2026
Trial IDNCT07613840 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with PAD who have undergone a revascularization procedure.

Probably not a fit

Patients whose coagulation profile does not differ meaningfully from standard treatment or who cannot tolerate the personalized regimen may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests whether a TARGET plan that uses thromboelastography with platelet mapping (TEG-PM) to customize antiplatelet therapy improves outcomes after lower-extremity revascularization for PAD. Participants are randomized to the personalized plan or standard treatment and receive blood tests at 1 week and at 1, 3, 6, 9, and 12 months to guide medication adjustments. The study looks at whether the personalized approach reduces graft/stent thrombosis, amputation, repeat procedures, bleeding, and death over 12 months. TEG-PM provides real-time profiling of coagulation and platelet response to antiplatelet drugs to inform therapy changes. Preliminary data suggest significant variability in platelet inhibition among PAD patients, supporting the need for individualized thromboprophylaxis.

Why it matters

Potential benefit: If successful, the personalized plan could lower clotting-related complications and improve limb-sparing outcomes.

How similar studies have gone: Prior observational data indicate platelet inhibition variability in PAD; whether a targeted approach improves outcomes remains to be proven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and/or closed revascularization.
* Patients at the age of 18 or older

Exclusion Criteria:

* Patients who are younger than 18 years old
* Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)
* Prisoners, defined as those who have been directly admitted from a correctional facility.
* No atherosclerosis
* Subject has active stomach ulcers
* Subject has severe hepatic impairment
* Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of \>1 year, the study team will consult with the

Where it's running

  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting
  • Salem Hospital (Mass General Brigham)
    Salem, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.